Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Doximity Inc’s stock clocked out at $54.29, down -13.25% from its previous closing price of $62.58. In other words, the price has decreased by -$13.25 from its previous closing price. On the day, 5.71 million shares were traded. DOCS stock price reached its highest trading level at $58.24 during the session, while it also had its lowest trading level at $53.3501.
Ratios:
To gain a deeper understanding of DOCS’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 11.58 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 32.58. For the most recent quarter (mrq), Quick Ratio is recorded 7.75 and its Current Ratio is at 7.75. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
On October 10, 2025, JP Morgan Downgraded its rating to Underweight which previously was Neutral but kept the price unchanged to $62.
Goldman Downgraded its Neutral to Sell on October 01, 2025, while the target price for the stock was maintained at $64.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 03 ’25 when Wampler Kira Scherer sold 2,000 shares for $66.44 per share. The transaction valued at 132,880 led to the insider holds 19,839 shares of the business.
KIRA WAMPLER bought 2,000 shares of DOCS for $132,880 on Nov 03 ’25. On Oct 10 ’25, another insider, Benjamin Regina M., who serves as the Director of the company, sold 5,000 shares for $70.84 each. As a result, the insider received 354,200 and left with 19,839 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DOCS now has a Market Capitalization of 10221247488 and an Enterprise Value of 9354148864. As of this moment, Doximity’s Price-to-Earnings (P/E) ratio for their current fiscal year is 43.30, and their Forward P/E ratio for the next fiscal year is 31.61. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.98. For the stock, the TTM Price-to-Sale (P/S) ratio is 16.37 while its Price-to-Book (P/B) ratio in mrq is 9.32. Its current Enterprise Value per Revenue stands at 15.055 whereas that against EBITDA is 37.036.
Stock Price History:
The Beta on a monthly basis for DOCS is 1.37, which has changed by -0.11363268 over the last 52 weeks, in comparison to a change of 0.12121439 over the same period for the S&P500. Over the past 52 weeks, DOCS has reached a high of $85.21, while it has fallen to a 52-week low of $42.36. The 50-Day Moving Average of the stock is -21.60%, while the 200-Day Moving Average is calculated to be -13.54%.
Shares Statistics:
It appears that DOCS traded 1.44M shares on average per day over the past three months and 1890370 shares per day over the past ten days. A total of 137.19M shares are outstanding, with a floating share count of 132.48M. Insiders hold about 29.27% of the company’s shares, while institutions hold 66.04% stake in the company. Shares short for DOCS as of 1760486400 were 4601746 with a Short Ratio of 3.21, compared to 1757894400 on 4823111. Therefore, it implies a Short% of Shares Outstanding of 4601746 and a Short% of Float of 3.45.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 16.0 analysts currently analyzing and rating the stock of Doximity Inc (DOCS).The consensus estimate for the next quarter is $0.33, with high estimates of $0.39 and low estimates of $0.26.
Analysts are recommending an EPS of between $1.67 and $1.35 for the fiscal current year, implying an average EPS of $1.56. EPS for the following year is $1.73, with 15.0 analysts recommending between $2.04 and $1.47.
Revenue Estimates
In. The current quarter, 16 analysts expect revenue to total $181.83M. It ranges from a high estimate of $192.21M to a low estimate of $180.3M. As of. The current estimate, Doximity Inc’s year-ago sales were $168.6MFor the next quarter, 16 analysts are estimating revenue of $150.26M. There is a high estimate of $158.71M for the next quarter, whereas the lowest estimate is $147.7M.
A total of 18 analysts have provided revenue estimates for DOCS’s current fiscal year. The highest revenue estimate was $664.29M, while the lowest revenue estimate was $625M, resulting in an average revenue estimate of $643.88M. In the same quarter a year ago, actual revenue was $570.4MBased on 18 analysts’ estimates, the company’s revenue will be $715.77M in the next fiscal year. The high estimate is $773.46M and the low estimate is $688.7M.
